Old and New Heparins
Overview
Authors
Affiliations
Heparin is an effective, relatively safe, inexpensive parenteral antithrombotic agent widely used in the prevention and treatment of thromboembolic disorders, but it has several limitations such as the marked intra- and inter-patient variability in its anticoagulant response, its poor bioavailability at low doses and its relatively narrow risk to benefit ratio. Low molecular weight heparins ( LMWHs), ultra LMWHs and synthetic pentasaccharides have been developed from heparin to overcome its limitations. The characteristics of these compounds are reviewed along with the description of their approved clinical uses.
Anticoagulation for people receiving long-term haemodialysis.
Natale P, Palmer S, Ruospo M, Longmuir H, Dodds B, Prasad R Cochrane Database Syst Rev. 2024; 1():CD011858.
PMID: 38189593 PMC: 10772979. DOI: 10.1002/14651858.CD011858.pub2.
Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.
Banik N, Yang S, Kang T, Lim J, Park J Int J Mol Sci. 2021; 22(19).
PMID: 34638867 PMC: 8509054. DOI: 10.3390/ijms221910524.
Preparation of low molecular weight heparin using an ultrasound-assisted Fenton-system.
Zhi Z, Li J, Chen J, Li S, Cheng H, Liu D Ultrason Sonochem. 2018; 52:184-192.
PMID: 30559077 PMC: 6475493. DOI: 10.1016/j.ultsonch.2018.11.016.
Abbas M Indian J Crit Care Med. 2017; 21(7):419-423.
PMID: 28808360 PMC: 5538088. DOI: 10.4103/ijccm.IJCCM_23_17.
Thrombolysis by chemically modified coagulation factor Xa.
Pryzdial E, Meixner S, Talbot K, Eltringham-Smith L, Baylis J, Lee F J Thromb Haemost. 2016; 14(9):1844-54.
PMID: 27359348 PMC: 5576980. DOI: 10.1111/jth.13402.